In the BRCA1(−) tumor model, CTLA4 blockades combined with PARPi induce protective anti-tumor immunity and significant survival benefit by locally inducing anti-tumor immunity and increasing levels of IFNγ [227]. Here, CTLA4 is linked to neoplasm.